Doliver Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Doliver Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.54M	Sell	304,328 -70,000	-19%	-$659K	0.55%	27
2026 Q2	$3.74M	Hold	374,328	–	–	0.85%	19
2026 Q1	$3.56M	Buy	374,328 +100,000	+36%	+$777K	0.81%	16
2025 Q4	$2.14M	Hold	274,328	–	–	0.54%	28
2025 Q3	$2.08M	Hold	274,328	–	–	0.54%	29
2025 Q2	$2.46M	Buy	274,328 +200,000	+269%	+$1.86M	0.67%	23
2025 Q1	$557K	Hold	74,328	–	–	0.16%	96
2024 Q4	$559K	Sell	74,328 -6,672	-8%	-$50.6K	0.16%	91
2024 Q3	$616K	Hold	81,000	–	–	0.17%	83
2024 Q2	$501K	Hold	81,000	–	–	0.14%	91
2024 Q1	$411K	Hold	81,000	–	–	0.12%	107
2023 Q4	$485K	Hold	81,000	–	–	0.15%	91
2023 Q3	$573K	Hold	81,000	–	–	0.17%	80
2023 Q2	$570K	Hold	81,000	–	–	0.17%	84
2023 Q1	$676K	Hold	81,000	–	–	0.21%	75
2022 Q4	$930K	Hold	81,000	–	–	0.31%	55
2022 Q3	$1.02M	Hold	81,000	–	–	0.38%	45
2022 Q2	$857K	Hold	81,000	–	–	0.3%	60
2022 Q1	$1.32M	Sell	81,000 -19,000	-19%	-$305K	0.42%	43
2021 Q4	$1.52M	Hold	100,000	–	–	0.48%	35
2021 Q3	$1.44M	Buy	+100,000	New	+$1.58M	0.48%	34

Other funds holding BCRX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

QTR Family Wealth Lake Mary, Florida $270M AUM 34.3% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

Doliver Advisors's BCRX Position: Q3 2026 in Review

Doliver Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 19% in Q3 2026, selling an estimated $659K and leaving 304,328 shares worth $2.54M. The position accounts for 0.55% of the portfolio, ranked #27.

Doliver Advisors first reported a position in BCRX in Q3 2021 and has held it in 21 quarters since. The position peaked at $3.74M in Q2 2026. 65 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

Doliver Advisors held 304,328 shares of BioCryst Pharmaceuticals worth $2.54M as of Q3 2026.
Doliver Advisors sold 70,000 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $659K.
BioCryst Pharmaceuticals made up 0.55% of Doliver Advisors's portfolio in Q3 2026, its #27 holding.
Doliver Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
Doliver Advisors's BioCryst Pharmaceuticals position peaked at $3.74M in Q2 2026.
65 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Doliver Advisors's 13F filing for Q3 2026, filed 1 Oct 2026.